Active Filter(s):
Details:
Letybo (Botulinum toxin type A) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients.
Lead Product(s): Botulinum Toxin A
Therapeutic Area: Dermatology Product Name: Letybo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Sihuan Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2024
Details:
LETYBO is indicated for temporary improvement in the appearance of moderate to severe glabellar frown lines in adults. It is currently available in 28 countries worldwide, with recent approvals in Europe and Canada.
Lead Product(s): LetibotulinumtoxinA
Therapeutic Area: Dermatology Product Name: Letybo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
Hugel plans to effectively deliver the efficacy and safety of Letybo (letibotulinumtoxinA) by providing training for local medical staff and conducting academic programs in cooperation with major chain clinics and key opinion leaders.
Lead Product(s): LetibotulinumtoxinA
Therapeutic Area: Dermatology Product Name: Letybo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2022
Details:
Letybo (letibotulinumtoxinA for injection) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients under 65 years of age.
Lead Product(s): LetibotulinumtoxinA
Therapeutic Area: Dermatology Product Name: Letybo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
The launch of saypha® VOLUME PLUS, a hyaluronic acid dermal filler, into the Canadian market will enhance the available line of saypha® dermal fillers, giving aesthetic medical professionals more creative power to design a truly bespoke experience for their patients.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Saypha
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022